Oppenheimer analyst Jay Olson maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) on November 11 and set a price target of $50.00. The company’s shares closed yesterday at $29.89.
When you buy through our links, we may earn a commission. Learn more› By Jenni Gritters and Chris Dixon A balance bike may be a little kid’s first introduction to zipping around on their own ...